Stockscreener 앱 받기
7.62
3.39%
0.24
시간 외 거래:
7.62
전일 마감가:
$7.38
열려 있는:
$7.45
하루 거래량:
772.86K
Relative Volume:
3.16
시가총액:
$507.71M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+16.85%
1개월 성능:
+12.70%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$7.38
$7.78
1주일 범위
$6.6099
$7.78
52주 변동 폭
$5.33
$7.9999
Niagen Bioscience Inc Stock (NAGE) Company Profile
명칭
Niagen Bioscience Inc
전화
310-388-6706
주소
10900 WILSHIRE BLVD, LOS ANGELES
NAGE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
7.62 | 507.71M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-08-16 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-08-11 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2022-03-08 | 개시 | ROTH Capital | Buy |
| 2019-10-16 | 개시 | Oppenheimer | Outperform |
| 2019-02-14 | 개시 | B. Riley FBR | Buy |
| 2017-11-27 | 재개 | H.C. Wainwright | Buy |
| 2017-09-25 | 개시 | Ladenburg Thalmann | Buy |
| 2017-01-03 | 개시 | Rodman & Renshaw | Buy |
모두보기
Niagen Bioscience Inc 주식(NAGE)의 최신 뉴스
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 - Bluefield Daily Telegraph
Is Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st
Niagen Bioscience Inc [NAGE] stock for 2,146 USD was acquired by Lopez Carlos Luis - knoxdaily.com
Is it possible to buy Niagen Bioscience Inc(NAGE) shares at a good price now? - uspostnews.com
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) market cap up US$51m last week, benefiting both individual investors who own 36% as well as insiders - Yahoo Finance
Supplement Maker Rebrands - Los Angeles Business Journal
Robert Fried Exercises Options, Realizes $173KNiagen Bioscience (NASDAQ:NAGE) - Benzinga
Market Resilience: Niagen Bioscience Inc (NAGE) Finishes Weak at 5.42, Down -3.56 - DWinneX
Niagen Bioscience Confirms Its Operations Remain Unaffected By New Tariffs - marketscreener.com
Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs - Business Wire
Niagen Bioscience maintains stability amid tariffs By Investing.com - Investing.com South Africa
Niagen Bioscience Stands Firm Despite Global Tariff Concerns - Finimize
Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments - MarketScreener
Niagen Bioscience maintains stability amid tariffs - Investing.com
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 30% Cheaper Price Remains In Tune With Revenues - simplywall.st
Growth Companies With High Insider Ownership For April 2025 - Yahoo Finance
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® - MarketScreener
H.C. Wainwright holds $11 target on Niagen Bioscience stock By Investing.com - Investing.com Canada
H.C. Wainwright holds $11 target on Niagen Bioscience stock - Investing.com
A Look At The Fair Value Of Niagen Bioscience, Inc. (NASDAQ:NAGE) - simplywall.st
Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN) - MarketScreener
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results - MarketScreener
Niagen Bioscience broadens NAD+ precursor IP portfolio with new patent - TipRanks
Niagen Bioscience secures new patent for NAD+ precursors - Investing.com
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms - Business Wire
Niagen Bioscience, Inc. Rings the Closing Bell - Nasdaq
ChromaDex Completes Name Change to Niagen Bioscience -March 19, 2025 at 09:29 am EDT - Marketscreener.com
Chromadex Rebrands to Niagen Bioscience, Inc. - TipRanks
ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science - The Bakersfield Californian
ChromaDex Corporation will Change its Ticker to NAGE from CDXC - marketscreener.com
ChromaDex changes name to Niagen Bioscience to home in on healthy aging - SupplySide Supplement Journal
Chromadex’s Strategic Rebranding and Promising Clinical Developments Justify Buy Rating - TipRanks
ChromaDex rebrands as Niagen Bioscience to reflect growth in supplement, pharmaceutical industries - NutraIngredients-USA.com
ChromaDex Changing Name To Niagen Bioscience While Shifting Focus To Rx NAD+ - insights.citeline.com
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025 - Bluefield Daily Telegraph
ChromaDex to rebrand as Niagen Bioscience and change ticker - Investing.com
Healthy Aging Leader ChromaDex Takes Center Stage at ROTH Conference Longevity Panel - Stock Titan
ChromaDex Capitalizes On Longevity Boom, But Valuation Remains High - Seeking Alpha
ChromaDex Corporation (NASDAQ:CDXC) Q4 2024 Earnings Call Transcript - Insider Monkey
When Will ChromaDex Reveal Its Q4 Performance? Key Date for NAD+ Leader's Financial Results - Stock Titan
ChromaDex to Present at Lytham Partners Healthcare Summit, Showcasing NAD+ Research Advances - StockTitan
Daré Bioscience, Inc. and ARPA-H Ring the Nasdaq Stock Market Closing Bell - Nasdaq
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide - Business Wire
Thorne acquires brain health formula partner in $5 million deal - SupplySide Supplement Journal
The proper role of pre-blends of nutrients in production of dietary supplements - SupplySide Supplement Journal
FDA Criminal Office Said to Be Examining Drug Ostarine in Dietary Supplements - SupplySide Supplement Journal
Technology disruption in the dietary supplement industry - SupplySide Supplement Journal
IV and Injection Offerings to Additional Leading Wellness Clinics - Business Wire
GMP Requirements for Softgels - SupplySide Supplement Journal
ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions - Business Wire
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024 - Business Wire
Niagen Bioscience Inc (NAGE) 재무 분석
Niagen Bioscience Inc (NAGE)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.12%
자본화:
|
볼륨(24시간):